Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED  

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Hot anti-cancer medicines  > Imbruvica CAS 936563-96-1 Ibrutinib

Imbruvica CAS 936563-96-1 Ibrutinib 

Payment Terms: T/T,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: MOS-new 3
Production Capacity: 100kg/year
Delivery Date: 7 days
Name 1: Ibrutinib
Appearance: white crystalline powder
Application: small-molecule inhibitor
Means of Transport: Ocean,Land,Air
Packing: according to the customer's...
Name: Imbruvica
CAS: 936563-96-1
Molecular weight: 440.5

Small molecule BTK inhibitors

Ibrutinib

CAS: 936563-96-1

Mechanism of action: Ibrutinib is a small molecule BTK inhibitor that binds covalently to the cysteine residue of the BTK active center, thereby inhibiting its activity. BTK stands for Bruton'styrosinekinase, which transmits signals in the BCR signaling pathway and cytokine receptor signaling pathway, and mediates B cell migration, chemotaxis, and adhesion. Preclinical studies have demonstrated that Ibrutinib can inhibit the proliferation and survival of malignant B cells.

Clinical trials: 111 patients who had received at least one treatment had a total response rate of 65.8% (complete response 17.1% + partial response 48.6%) after treatment with ibrutinib. The median duration of response was 17.5 months.

Supplement: Ibrutinib is the second new drug approved by the FDA's breakthrough drug channel (the first is obinutuzumab), and also enjoys two other FDA buffs and seven years of administrative protection after listing. Due to the addition of multiple accelerated buffs, the clinical trial of the drug appeared to be very simple, with only 111 patients enrolled, and the clinical endpoint was response rate rather than survival. Mantle cell lymphoma is a rare non-Hodgkin's lymphoma. The FDA previously approved bortezomib and lenalidomide in 2006 and 2013 to treat the disease. Ibrutinib is a key product that Johnson & Johnson bought from Pharmacyclics at a high price. In addition to treatment of mantle cell lymphoma, it is also used for chronic lymphocytic leukemia and small lymphocytic lymphoma.


We can customize according to customer's requirement

if you have any question pls mail us or call us


bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: